Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

243 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
Carlini P, Bria E, Giannarelli D, Ferretti G, Felici A, Papaldo P, Fabi A, Nisticò C, Di Cosimo S, Ruggeri EM, Milella M, Mottolese M, Terzoli E, Cognetti F. Carlini P, et al. Among authors: mottolese m. Cancer. 2005 Oct 1;104(7):1335-42. doi: 10.1002/cncr.21339. Cancer. 2005. PMID: 16088965 Free article. Review.
Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients.
Fabi A, Ferretti G, Papaldo P, Salesi N, Ciccarese M, Lorusso V, Carlini P, Carpino A, Mottolese M, Cianciulli AM, Giannarelli D, Sperduti I, Felici A, Cognetti F. Fabi A, et al. Among authors: mottolese m. Cancer Chemother Pharmacol. 2006 May;57(5):615-23. doi: 10.1007/s00280-005-0116-2. Epub 2005 Sep 15. Cancer Chemother Pharmacol. 2006. PMID: 16163541 Clinical Trial.
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Fabi A, Metro G, Papaldo P, Mottolese M, Melucci E, Carlini P, Sperduti I, Russillo M, Gelibter A, Ferretti G, Tomao S, Milella M, Cognetti F. Fabi A, et al. Among authors: mottolese m. Cancer Chemother Pharmacol. 2008 Sep;62(4):717-25. doi: 10.1007/s00280-007-0650-1. Epub 2007 Dec 6. Cancer Chemother Pharmacol. 2008. PMID: 18071704 Clinical Trial.
Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies.
Fabi A, Metro G, Ferretti G, Giannarelli D, Di Cosimo S, Papaldo P, Mottolese M, Carlini P, Felici A, Russillo M, Cognetti F. Fabi A, et al. Among authors: mottolese m. Breast. 2008 Oct;17(5):499-505. doi: 10.1016/j.breast.2008.03.006. Epub 2008 May 1. Breast. 2008. PMID: 18450443 Free article. Review.
HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care.
Fabi A, Di Benedetto A, Metro G, Perracchio L, Nisticò C, Di Filippo F, Ercolani C, Ferretti G, Melucci E, Buglioni S, Sperduti I, Papaldo P, Cognetti F, Mottolese M. Fabi A, et al. Among authors: mottolese m. Clin Cancer Res. 2011 Apr 1;17(7):2055-64. doi: 10.1158/1078-0432.CCR-10-1920. Epub 2011 Feb 9. Clin Cancer Res. 2011. PMID: 21307144
A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease.
Papaldo P, Fabi A, Ferretti G, Mottolese M, Cianciulli AM, Di Cocco B, Pino MS, Carlini P, Di Cosimo S, Sacchi I, Sperduti I, Nardoni C, Cognetti F. Papaldo P, et al. Among authors: mottolese m. Ann Oncol. 2006 Apr;17(4):630-6. doi: 10.1093/annonc/mdj110. Epub 2006 Jan 12. Ann Oncol. 2006. PMID: 16410363 Free article. Clinical Trial.
Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy.
Botti C, Buglioni S, Benevolo M, Giannarelli D, Papaldo P, Cognetti F, Vici P, Di Filippo F, Del Nonno F, Venanzi FM, Natali PG, Mottolese M. Botti C, et al. Among authors: mottolese m. Clin Cancer Res. 2004 Feb 15;10(4):1360-5. doi: 10.1158/1078-0432.ccr-1092-03. Clin Cancer Res. 2004. PMID: 14977837
Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?
Papaldo P, Ferretti G, Di Cosimo S, Giannarelli D, Marolla P, Lopez M, Cortesi E, Antimi M, Terzoli E, Carlini P, Vici P, Botti C, Di Lauro L, Naso G, Nisticò C, Mottolese M, Di Filippo F, Ruggeri EM, Ceribelli A, Cognetti F. Papaldo P, et al. Among authors: mottolese m. J Clin Oncol. 2006 Jul 1;24(19):3048-55. doi: 10.1200/JCO.2005.02.9488. Epub 2006 Jun 12. J Clin Oncol. 2006. PMID: 16769988 Clinical Trial.
243 results